Provolol Pharmaceutical (000739.SZ): Pentoxifylline extended-release tablets obtained drug registration certificate

According to Zhitong Finance App, Prorow Pharmaceutical (000739.SZ) issued an announcement. Recently, Zhejiang Pulo Kangyu Pharmaceutical Co., Ltd. (hereinafter referred to as “Kangyu Pharmaceutical”), a holding subsidiary of the company, received the “Drug Registration Certificate” for pentoxifylline sustained-release tablets issued by the State Drug Administration. Pentoxifylline extended-release tablets are peripheral vasodilators. Used for peripheral vascular diseases, including intermittent claudication and resting pain. According to relevant data, the domestic market size of pentoxifylline extended-release tablets in 2025 is about 52.27 million tablets, with a sales amount of about 262 million yuan.